Listing 5.11 Small Intestine Transplantation in 2026: The Automatic 12 Month SSDI Approval from Transplant Date, How TPN Weaning and Enteral Autonomy Play Into the CDR, When Rejection Episodes and PTLD and Graft-Versus-Host Disease Extend the Disability Period, and How Pre-Transplant Intestinal Failure Under 5.07 Establishes an Earlier Onset Date

By Anthony Albert, Benefits Research Director. Published July 25, 2026.

Small intestine transplantation is one of the rarest solid organ transplants in the US. Only about 80 to 120 adult intestine transplants happen per year nationally, per UNOS registry data. That is fewer than the total number of hearts transplanted at some individual centers. And yet the SSA Blue Book has a dedicated listing, 5.11, that gives you 1 year of automatic disability from the date of transplantation.

If you got here searching for small intestine transplant disability rules, you probably already know how hard this road is. Most intestine transplant recipients have spent years on total parenteral nutrition (TPN) through a central venous catheter. Many have had recurrent catheter infections, TPN-associated liver disease, or exhausted their peripheral venous access. The transplant itself is a chance to eat again and to stop the central line, but the immediate post-transplant course is often brutal.

SSA recognizes all of this. Listing 5.11 is unconditional for the first 12 months. Section 5.00G explains that recipients of liver, small intestine, and pancreas transplants generally meet the disability definition before surgery, and that the 1 year clock does not restrict the actual disability onset date. Most intestine recipients qualified under Listing 5.07 (Intestinal Failure) for years before the transplant.

This article covers the exact 5.11 text, how the 12 month window works, what happens at the CDR, common complications that extend disability past 12 months, pediatric 105.11, and how pre-transplant TPN records under 5.07 anchor a much earlier onset date. Four worked cases at the end.

The Listing 5.11 Text

Section 5.00G groups liver (5.09), small intestine (5.11), and pancreas (5.12) transplantation together with identical rules. If you receive any of these transplants, SSA considers you disabled under the listing for 1 year from the transplant date. After that, SSA evaluates residual impairment based on:

• Adequacy of post-transplant function (both graft function and nutrient absorption)
• Requirement for post-transplant antiviral therapy (usually CMV prophylaxis)
• Frequency and severity of rejection episodes (higher in intestine than in any other solid organ)
• Comorbid complications (infections, PTLD, renal dysfunction, TPN dependency)
• All adverse treatment effects

SSA notes explicitly that most intestine transplant patients meet the definition of disability before the transplant. The 12 month clock does not restrict onset date. Onset is determined based on the facts of the case, typically anchored by Listing 5.07 (Intestinal Failure) records.

What "Consider Under a Disability for 1 Year" Means for Intestine Recipients

The 12 month window is automatic. No functional testing during this period. No proof of persistent complications required. Just the transplant date and the fact of transplantation. What matters practically:

1. Submit the transplant operative note confirming date and graft type (isolated intestine, combined liver-intestine, or full multivisceral).
2. Submit the transplant admission discharge summary showing early complications, if any.
3. Do not wait for the 12 months to end before submitting complications documentation. Complications in months 3 through 12 build the record for the CDR.
4. File as soon as possible after transplant. If you had not filed pre-transplant, file immediately post-transplant. Disability onset can still be set to the pre-transplant Listing 5.07 date.

Types of Small Intestine Transplant Under 5.11

Isolated small intestine transplant

About 40 to 50 percent of intestine transplants. Just the small bowel is transplanted, sometimes with the ascending colon. Indication is short bowel syndrome or motility disorder without significant liver disease. Best outcomes among intestine transplant categories. One-year graft survival 75 to 85 percent per UNOS 2024 data.

Combined liver-intestine transplant

About 30 to 40 percent. Liver and intestine transplanted together. Indication is intestinal failure with TPN-associated liver disease progressing to cirrhosis. Also indicated for select metabolic disorders. Under 5.11 rules the intestine listing applies, but the liver component also independently qualifies under 5.09. Either listing gives 1 year auto.

Multivisceral transplant

About 15 to 25 percent. Stomach, duodenum, pancreas, small intestine, and liver transplanted together. Sometimes with kidney. Indication is diffuse motility disorder (like chronic intestinal pseudo-obstruction, or CIPO), abdominal malignancy invading multiple organs (like desmoid tumors or slow-growing neuroendocrine tumors), or catastrophic vascular event. Multivisceral has the highest rejection and GVHD rates but is the only option for some patients.

Modified multivisceral

About 5 to 10 percent. Multivisceral without the liver. Indication is diffuse motility disorder without significant liver disease. Same 5.11 rules apply.

Indications for Small Intestine Transplant That Route Through 5.11

Small intestine transplant is not the first-line treatment for intestinal failure. TPN is the standard. Transplant is reserved for TPN failure or for progressive TPN-associated liver disease. Indications:

Short bowel syndrome (SBS)

Most common indication. Loss of small bowel from ischemic events (superior mesenteric artery thrombosis or embolism, midgut volvulus, necrotizing enterocolitis in pediatrics), trauma (multiple resections), Crohn's disease with cumulative resections, radiation enteritis, or gastroschisis in pediatrics. TPN required when remaining bowel cannot maintain nutrition orally.

TPN failure or TPN-associated complications

Includes TPN-associated liver disease (TPN-ALD), also called intestinal failure-associated liver disease (IFALD), with progression to cirrhosis; loss of central venous access with less than 2 remaining sites (both subclavians thrombosed, both internal jugulars thrombosed, femoral use exhausted); recurrent catheter-related bloodstream infections (three or more per year); recurrent episodes of severe TPN-related dehydration or electrolyte disturbance.

Motility disorders

Chronic intestinal pseudo-obstruction (CIPO, both primary and secondary forms), visceral myopathies, visceral neuropathies. These conditions cause the intestines to function poorly despite anatomical presence. Transplant is definitive only if the graft can be dysmotility-free.

Diffuse abdominal disease

Desmoid tumors (associated with familial adenomatous polyposis or Gardner syndrome) that invade the mesentery. Slow-growing neuroendocrine tumors. Extensive superior mesenteric vessel thrombosis with organ involvement. Multivisceral or modified multivisceral transplant may be the only definitive treatment.

Congenital enteropathies (pediatric)

Microvillous inclusion disease (MVID), tufting enteropathy, congenital enterocyte heparan sulfate deficiency. These conditions cause TPN dependency from birth. Pediatric intestinal transplant.

Pre-Transplant Onset Under Listing 5.07 Intestinal Failure

Nearly every adult small intestine transplant recipient qualified under Listing 5.07 in the months or years before transplant. 5.07 has two paragraphs:

5.07A: Intestinal failure requiring daily parenteral nutrition via central venous catheter for at least 12 consecutive months

Requires documentation of daily TPN via central venous catheter for at least 12 months. This is the standard path for adult intestine transplant candidates. The date TPN began through a central line becomes the earliest disability onset date.

5.07B: Not applicable to adults (pediatric-only under 105.07)

Documenting 5.07A is straightforward: TPN prescription records, home infusion records, catheter placement note. The 12 consecutive months does not have to be the 12 months immediately before transplant. It can be any 12 month period during the intestinal failure course.

Example: patient starts TPN in January 2023 after superior mesenteric artery thrombosis with 50 cm remaining small bowel. Continuous TPN through January 2024 meets 5.07A. Transplant occurs in June 2026. Disability onset is January 2024 (12 months after TPN started) or earlier if the patient files during that 12 month period. Retroactive benefits back to January 2024 possible.

The Lung and Liver Comparison

Here is where 5.11 differs from other transplants in a way that matters for the CDR:

• Lung transplant (3.11): 3 years automatic, then residual under 3.00M
• Liver transplant (5.09): 1 year automatic, then residual under 5.00G
• Heart transplant (4.09): 1 year automatic, then residual under 4.00H
• Kidney transplant (6.04): 1 year automatic, then residual under 6.00C2
• Bone marrow/stem cell transplant (7.17): 12 months from infusion, then residual under 7.00G
• Small intestine transplant (5.11): 1 year automatic, then residual under 5.00G
• Pancreas transplant (5.12): 1 year automatic, then residual under 5.00G

Only lung transplant gets 3 years automatic. Intestine transplant gets the standard 1 year, but has the highest rate of complications after year 1 of any solid organ transplant. This asymmetry makes CDR preparation especially important.

What Happens at the 12 Month CDR

Under POMS DI 28010.030, Listing 5.11 is a "listing with a specified timeframe" and triggers CDR at 12 to 15 months. SSA reviews residual impairment under the 5.00G factors:

1. Adequacy of post-transplant function

Two things matter here: graft function and enteral autonomy.

• Graft function: intestinal biopsy findings (rejection or not), ileostomy output volume and character, absorption studies (D-xylose test if used, citrulline levels), stool studies, endoscopic surveillance findings.
• Enteral autonomy: whether the recipient has stopped TPN and is fully oral-fed. Registry data shows 60 to 75 percent achieve enteral autonomy by 12 months. Those still on TPN at 12 months typically have complications extending disability.

2. Post-transplant antiviral therapy

CMV prophylaxis is standard for the first 6 to 12 months with valganciclovir. CMV enteritis and CMV pneumonitis are common complications. Persistent CMV viremia may require prolonged ganciclovir. HHV6 and EBV are also monitored.

3. Rejection episodes

Intestine transplant has the highest acute cellular rejection (ACR) rate of any solid organ. ACR occurs in 30 to 50 percent of recipients within the first year. Diagnosed by ileal biopsy with grading (mild, moderate, severe). Treatment escalates from steroid pulse to anti-thymocyte globulin (ATG) to alemtuzumab. Chronic rejection is often silent, presenting late with graft failure. Antibody-mediated rejection (AMR) requires donor-specific antibody (DSA) testing.

4. Comorbid complications

Infections are the leading cause of death post-transplant. Bacterial (line infections, translocation), viral (CMV, EBV, HHV6, adenovirus), fungal (Candida, aspergillus), and parasitic. Post-transplant lymphoproliferative disorder (PTLD) occurs in 15 to 25 percent of intestine transplant recipients, higher than any other solid organ. Graft-versus-host disease (GVHD) occurs in 5 to 10 percent due to the large lymphoid mass in transplanted bowel. Renal dysfunction from calcineurin toxicity is universal, with 20 to 25 percent requiring dialysis by 5 years per registry data. Neurologic complications (seizures, PRES posterior reversible encephalopathy syndrome).

5. Adverse treatment effects

Tacrolimus is the standard immunosuppressant plus induction with alemtuzumab or ATG. Steroids are commonly weaned. Common adverse effects: renal dysfunction, tremor, hypertension, hyperglycemia, hyperlipidemia, immunosuppression-related secondary malignancies (skin cancers, PTLD).

Extending Disability Past 12 Months

Registry data shows intestine transplant recipients have among the lowest return-to-work rates of any organ recipient. Common paths for continued disability past 12 months:

Ongoing TPN dependency

Recipients who cannot achieve enteral autonomy remain functionally identical to pre-transplant TPN dependency, though now with a transplanted bowel. Ongoing TPN via central line qualifies under 5.07A (which requires 12 consecutive months). If TPN post-transplant is expected to continue 12 more months, 5.07A can be met on a rolling basis.

Rejection episodes with dysmotility or malabsorption

Chronic rejection with graft dysfunction produces the same clinical picture as short bowel syndrome, including weight loss (may meet 5.08 BMI under 17.50 twice within 6 months 60 days apart) and malabsorption.

PTLD evaluated under 13.28 (blood and lymphatic cancer)

PTLD is a form of B-cell lymphoma in most cases. If distant or refractory, meets 13.05 (lymphomas). Aggressive treatment (rituximab, chemotherapy, reduction of immunosuppression) often supports continued disability.

Renal dysfunction from calcineurin toxicity meets 6.03, 6.04, or 6.05

20 to 25 percent of intestine transplant recipients require dialysis by 5 years. Meets 6.03 (dialysis) or 6.05 (CKD with GFR under 30 for stage 4).

Retransplantation resets 5.11

Intestine retransplantation occurs in 5 to 10 percent of first transplants. The 5.11 clock resets to the retransplant date.

GVHD evaluated under multiple body systems

Cutaneous GVHD (8.05, 8.06), pulmonary GVHD (3.02), hepatic GVHD (5.05), GI GVHD (5.08). Some recipients have GVHD affecting multiple systems.

Pediatric Listing 105.11

Pediatric small intestine transplant recipients qualify under Listing 105.11 with identical language: 1 year from transplant date, then residual impairment evaluation. Pediatric indications:

• Gastroschisis with extensive bowel loss
• Necrotizing enterocolitis with catastrophic resection
• Midgut volvulus with SMA thrombosis
• Congenital enteropathies (MVID, tufting enteropathy)
• Total intestinal aganglionosis (severe Hirschsprung's)
• CIPO

Pediatric intestinal transplant volume is small (about 30 to 40 per year in the US). Concentrated at Children's Hospital of Pittsburgh (UPMC), Children's Hospital of Philadelphia, Georgetown University, Miami/Jackson Memorial, and a few other centers. Pre-transplant kids typically qualify under 105.07 (need for supplemental daily enteral feeding via gastrostomy under age 3) or 105.11-equivalent TPN records.

Documentation Checklist

1. Pre-transplant medical records: underlying diagnosis (SBS, motility disorder, TPN-ALD, malignancy), bowel resection operative notes, remaining bowel measurements, central venous catheter history
2. Complete TPN records for at least 12 consecutive months (5.07A) with home infusion pharmacy records, PICC or tunneled catheter placement notes, catheter infection history, TPN complication notes
3. Liver function progression if TPN-ALD (LFT trend, MELD-Na if cirrhosis, transient elastography)
4. Transplant evaluation notes from the transplant team, UNOS listing date, MELD adjustment for TPN-ALD if applicable
5. Transplant operative note with exact date and graft type (isolated intestine vs combined liver-intestine vs multivisceral vs modified multivisceral)
6. Transplant discharge summary and early complications
7. Post-transplant follow-up notes at 1 month, 3 months, 6 months, and 12 months
8. Ileal biopsies with rejection grading
9. Immunosuppression medication list (tacrolimus, steroids, mycophenolate; induction with alemtuzumab or ATG)
10. Antiviral therapy record (valganciclovir for CMV prophylaxis)
11. Complication documentation: CMV viral loads, EBV viral loads (PTLD risk), stool studies, absorption markers (citrulline), enteral autonomy status (percentage of caloric needs met orally)
12. Renal function trend (creatinine, eGFR) for CNI nephrotoxicity
13. Treating transplant surgeon or GI transplant physician narrative statement or RFC

Four Worked Cases

Case One, Ana, 42, Pennsylvania

Ana had superior mesenteric artery thrombosis at age 38 with resection of most small bowel. Left with 25 cm of jejunum anastomosed to colon. TPN dependent since January 2023 through a tunneled Hickman catheter. Two catheter-related bloodstream infections in 2024 (Staph aureus, Enterococcus). TPN-ALD with liver biopsy showing stage 3 fibrosis by June 2025. UNOS listed for combined liver-intestine transplant. Received transplant on March 8, 2026, at UPMC. She filed for SSDI in June 2024. Disability onset established at January 15, 2024 (12 months after TPN started, meeting 5.07A). Retroactive benefits from July 2023 (5 month waiting period). Automatic disability through March 7, 2027. CDR scheduled at 15 months.

Case Two, Marcus, 55, Florida

Marcus has chronic intestinal pseudo-obstruction (CIPO) from mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). TPN dependent for 6 years. Received modified multivisceral transplant (stomach, duodenum, pancreas, small intestine, without liver) at Miami on October 15, 2025. Post-op complicated by A2 rejection at day 30 (treated with steroid pulse and ATG), CMV enteritis at day 90 (treated with IV ganciclovir), and PTLD diagnosed at day 200 (EBV-driven B-cell lymphoma, treated with rituximab plus reduced immunosuppression). At 12 month CDR (October 2026), PTLD in partial remission but ongoing rituximab. Meets 13.05 (lymphoma) with active treatment. SSDI continues.

Case Three, Elena, 4, Illinois

Elena has microvillous inclusion disease (MVID). TPN dependent from age 1 month. Central line infections requiring 5 hospitalizations by age 3. TPN-ALD progressing. Approved under 105.07 (need for supplemental daily enteral feeding) from age 1. Combined liver-intestine transplant at CHOP on August 10, 2025 at age 3. Post-op course complicated by CMV disease at day 60 and A2 rejection at day 120. At 12 month CDR (August 2026), enteral autonomy 60 percent (still on partial TPN), FTT (failure to thrive) with weight below 3rd percentile. SSI benefits continue under 5.11 residual + growth failure documentation + partial TPN dependency approaching 5.07A criteria.

Case Four, David, 48, Texas

David has short bowel syndrome from midgut volvulus at age 40. Left with 40 cm of jejunum with intact ileocecal valve. TPN dependent 8 years. Isolated small intestine transplant at Baylor Dallas on May 20, 2025. Uncomplicated post-op. Achieved enteral autonomy at 8 months. No rejection episodes. At 12 month CDR (May 2026), fully oral-fed, normal LFTs, mild CNI nephropathy with creatinine 1.4 (eGFR 55). Returns to part-time work at month 14 and reaches SGA at month 20. SSDI terminates at month 22 under medical improvement per 20 CFR 404.1594. Trial work period rules apply on return-to-work timing.

Denial Counters

Denial reason: 12 months not yet elapsed from transplant date

5.11 does not require 12 months to elapse before filing. The 1 year rule applies from transplant date. File as soon as possible, even pre-transplant.

Denial reason: DDS wants proof of severity during the 12 month window

The 5.11 rule is unconditional. No severity proof required during the 12 month window. Cite 5.00G explicitly. Attach the operative note and discharge summary.

Denial reason: onset date set at transplant date, not pre-transplant

Under 5.00G and 5.07A, onset can be established months or years before transplant based on TPN dependency. Submit 12 consecutive months of TPN records with central line documentation. Onset can be set to the first TPN infusion date if that TPN then continued for at least 12 months.

Denial reason: CDR terminates at 12 months despite continuing TPN

Appeal within 60 days. Elect to continue benefits during appeal (10 day rule). Ongoing TPN dependency meets 5.07A independently of the 5.11 clock. Submit current TPN records and note that the recipient has not achieved enteral autonomy.

Denial reason: DDS argues the transplant "cured" the intestinal failure

Registry data shows only 60 to 75 percent achieve enteral autonomy at 12 months. Chronic rejection with graft dysfunction produces the same clinical picture as pre-transplant short bowel syndrome. Submit ileal biopsies, absorption studies, and stool volume records. Also submit body system referrals for CNI nephropathy, PTLD, or GVHD if applicable.

State Considerations

Adult and pediatric intestine transplant centers are highly concentrated. High-volume US centers include hospitals in Pennsylvania (Children's Hospital of Pittsburgh UPMC, historically the highest volume center), Florida (Jackson Memorial Miami, high volume adult multivisceral), Nebraska (Nebraska Medicine, high volume adult intestinal transplant), Texas (Baylor Dallas), Washington DC (Georgetown), California (UCLA, Cedars-Sinai), New York (Mount Sinai, Weill Cornell), and Illinois (Northwestern).

Pediatric intestine transplant concentrates at CHP Pittsburgh, CHOP Philadelphia, Cincinnati Children's, Miami Jackson, Boston Children's, and Nebraska Medicine.

Because intestine transplant is so rare, travel to a high-volume center is common. Post-transplant follow-up may be done partially at the transplant center and partially at a local GI or transplant specialist. This split care can complicate SSDI documentation, so make sure the local physician has full records from the transplant center.

Related Blue Book Reading

• Listing 5.07 Intestinal Failure
• Listing 5.08 Weight Loss Due to Any Digestive Disorder
• Listing 5.09 Liver Transplantation
• Listing 5.12 Pancreas Transplantation
• Listing 3.11 Lung Transplantation
• Listings 6.03 / 6.04 / 6.05 Chronic Kidney Disease and Kidney Transplant

Frequently Asked Questions